Acceleron names new chair of board
This article was originally published in Scrip
Executive Summary
Acceleron Pharma, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic candidates that regulate cellular growth and repair, has appointed Dr Francois Nader chair of its board of directors. Dr Nader joined the Acceleron board in December 2014. Most recently he was president, CEO and director of NPS Pharma through the recent acquisition of NPS by Shire.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.